GEN-MKT-18-7897-A
Jan 13, 2025 | Blogs, Pharma, ZenoTOF 7600 system | 0 comments
Read time: 2 minutes
It is no secret that (bio)pharmaceutical research and development is complex, both scientific and regulatory processes. Working for a contract research organization and more recently for SCIEX has provided an interesting perspective on trends the market experiences that affect many of us.
Outsourcing
It has been my experience that advancements in technology, particularly in mass spectrometry, have significantly transformed the capabilities and roles of Contract Development and Manufacturing Organizations (CDMOs) and Contract Research Organizations (CROs) in the drug development life cycle. High-resolution mass spectrometry (HRMS) has revolutionized the characterization of complex molecules, enabling precise identification of potential drug candidates and a deeper understanding of their mechanisms of action. Techniques like tandem mass spectrometry (MS/MS) and advanced fragmentation methods such as Electron-Activated Dissociation (EAD) from SCIEX allow for detailed structural elucidation and quantitation of biomolecules, facilitating the development of more targeted and effective therapies.
Artificial intelligence and machine learning
Integrating artificial intelligence (AI) and machine learning (ML) algorithms with mass spectrometry data enhances the potential of CDMOs and CROs by providing predictive insights and optimization strategies for drug discovery and manufacturing processes, improving efficiency and decision-making.
Advanced techniques like native mass spectrometry allow the study of biomolecules in their natural state, aiding research on protein complexes and interactions critical for biologics and personalized medicine. As technology continues to evolve, mass spectrometry will further enhance the efficiency, accuracy, and scope of services offered by CDMOs and CROs, driving innovation in drug development, and leading to the discovery of novel new medicines.
Biosecure Act
Looking forward I expect, the Biosecure Act will undoubtedly complicate biopharmaceutical business, especially in Asia, and this shift is likely to reshape the global biotech landscape. U.S. firms will face more hurdles during collaborations, particularly around gene-editing and sensitive pathogen research. Tightening biosecurity regulations may cause U.S. companies to seek research partners and suppliers based in regions that align better with these new standards, meaning new places may be seen as attractive hubs for innovation, partnerships, and investments. I expect we’ll see a more diversified global distribution of biotech work.
For more information about how SCIEX can support you please visit our website, here>
In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.
CE‑SDS remains a cornerstone assay for characterizing fragmentation, aggregation, and product‑related impurities in therapeutic proteins. UV detection has been the long‑standing standard. However, it frequently struggles with baseline noise, limited sensitivity for minor fragments, and subjective integration.
At SCIEX, innovation doesn’t stop at instruments; it extends to how you interact with your LC-MS/MS or CE systems every day. That’s why we’re excited to introduce the SCIEX Now spring 2026 improvements: a set of meaningful enhancements shaped directly by your feedback.
Posted by
You must be logged in to post a comment.
Share this post with your network